Personalized Medicine in 2011: Some Successes, Slow Progress, Continued Economic Woes
January 04, 2012
Personalized Medicine in 2011: Some Successes, Slow Progress, Continued Economic Woes
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Qiagen's Experience Developing KRAS CDx for Erbitux Yields Lessons for Rx/Dx Development
November 28, 2012 / Pharmacogenomics Reporter - PGx Drugs Xalkori, Zelboraf Show Strong Growth in First Quarter of 2013
May 1, 2013 / Pharmacogenomics Reporter - Personalized Medicine in 2012: Industry Takes a Wait-and-See Approach Due to Market Unknowns
January 9, 2013 / Pharmacogenomics Reporter - Pfizer, Roche Officials Share Lessons Learned from Rx/Dx Co-development of Xalkori and Zelboraf
February 29, 2012 / Pharmacogenomics Reporter - FDA Official Says Personalized Medicine Regulation Taking Shape Following Zelboraf, Xalkori Success
February 1, 2012 / Pharmacogenomics Reporter